BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30390673)

  • 21. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes.
    Gilman S; Koeppe RA; Nan B; Wang CN; Wang X; Junck L; Chervin RD; Consens F; Bhaumik A
    Neurology; 2010 May; 74(18):1416-23. PubMed ID: 20439843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes.
    Kaiserova M; Chudackova M; Prikrylova Vranova H; Mensikova K; Kastelikova A; Stejskal D; Kanovsky P
    Neurodegener Dis; 2021; 21(1-2):30-35. PubMed ID: 34695830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism.
    Constantinescu R; Rosengren L; Eriksson B; Blennow K; Axelsson M
    Acta Neurol Scand; 2019 Aug; 140(2):147-156. PubMed ID: 31070772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Swallow tail sign on susceptibility map-weighted imaging (SMWI) for disease diagnosing and severity evaluating in parkinsonism.
    Liu X; Wang N; Chen C; Wu PY; Piao S; Geng D; Li Y
    Acta Radiol; 2021 Feb; 62(2):234-242. PubMed ID: 32380911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flt3 ligand does not differentiate between Parkinsonian disorders.
    Silajdžić E; Constantinescu R; Holmberg B; Björkqvist M; Hansson O
    Mov Disord; 2014 Sep; 29(10):1319-22. PubMed ID: 25044107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP.
    Mangesius S; Hussl A; Krismer F; Mahlknecht P; Reiter E; Tagwercher S; Djamshidian A; Schocke M; Esterhammer R; Wenning G; Müller C; Scherfler C; Gizewski ER; Poewe W; Seppi K
    Parkinsonism Relat Disord; 2018 Jan; 46():47-55. PubMed ID: 29126761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative susceptibility mapping differentiates between parkinsonian disorders.
    Sjöström H; Granberg T; Westman E; Svenningsson P
    Parkinsonism Relat Disord; 2017 Nov; 44():51-57. PubMed ID: 28886909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy.
    Compta Y; Giraldo DM; Muñoz E; Antonelli F; Fernández M; Bravo P; Soto M; Cámara A; Torres F; Martí MJ;
    Parkinsonism Relat Disord; 2018 Jan; 46():16-23. PubMed ID: 29107645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: Which index better distinguishes Progressive Supranuclear Palsy patients with a low degree of diagnostic certainty from patients with Parkinson Disease?
    Nigro S; Morelli M; Arabia G; Nisticò R; Novellino F; Salsone M; Rocca F; Quattrone A
    Parkinsonism Relat Disord; 2017 Aug; 41():31-36. PubMed ID: 28487107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification.
    Huppertz HJ; Möller L; Südmeyer M; Hilker R; Hattingen E; Egger K; Amtage F; Respondek G; Stamelou M; Schnitzler A; Pinkhardt EH; Oertel WH; Knake S; Kassubek J; Höglinger GU
    Mov Disord; 2016 Oct; 31(10):1506-1517. PubMed ID: 27452874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Santangelo G; Cuoco S; Pellecchia MT; Erro R; Barone P; Picillo M
    J Neurol; 2018 Nov; 265(11):2602-2613. PubMed ID: 30178175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corneal confocal microscopy demonstrates varying degrees of neurodegeneration in atypical parkinsonian disorders.
    Lim SH; Ferdousi M; Bhattacharjee S; Kalteniece A; Mahfoud ZR; Petropoulos IN; Malik RA; Kobylecki C; Silverdale M
    Parkinsonism Relat Disord; 2023 Dec; 117():105899. PubMed ID: 37948830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SCOPA-AUT scale in different parkinsonisms and its correlation with (123) I-MIBG cardiac scintigraphy.
    Berganzo K; Tijero B; Somme JH; Llorens V; Sánchez-Manso JC; Low D; Iodice V; Vichayanrat E; Mathias CJ; Lezcano E; Zarranz JJ; Gómez-Esteban JC
    Parkinsonism Relat Disord; 2012 Jan; 18(1):45-8. PubMed ID: 21908227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Finger tapping analysis in patients with Parkinson's disease and atypical parkinsonism.
    Djurić-Jovičić M; Petrović I; Ječmenica-Lukić M; Radovanović S; Dragašević-Mišković N; Belić M; Miler-Jerković V; Popović MB; Kostić VS
    J Clin Neurosci; 2016 Aug; 30():49-55. PubMed ID: 27343040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiomics on routine T1-weighted MRI can delineate Parkinson's disease from multiple system atrophy and progressive supranuclear palsy.
    Tupe-Waghmare P; Rajan A; Prasad S; Saini J; Pal PK; Ingalhalikar M
    Eur Radiol; 2021 Nov; 31(11):8218-8227. PubMed ID: 33945022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
    Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
    J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.
    Holmberg B; Johnels B; Blennow K; Rosengren L
    Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Kim JM; Jeong HJ; Bae YJ; Park SY; Kim E; Kang SY; Oh ES; Kim KJ; Jeon B; Kim SE; Cho ZH; Kim YB
    Parkinsonism Relat Disord; 2016 May; 26():47-54. PubMed ID: 26951846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.